UBS Maintains Buy on AdaptHealth, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 64.6%

Neg 64.6% Neu 0% Pos 0%

UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $15 to $14.

Comments

No comments yet. Be the first!